GlaxoSmithKline News and Research

RSS

Nano-enabled drug discovery solutions will generate revenues of $1.3 billion in 2009

According to a new report by NanoMarkets, an industry consultancy based here, nano-enabled drug discovery solutions will generate revenues of $1.3 billion in 2009 and grow to $2.5 billion in 2012.

8 Mar 2005

Who would have thought we needed to study men for a cancer that targets women?

Who would have thought we needed to study men for a cancer that targets women? Anna Giuliano, Ph.D., at the H. Lee Moffitt Cancer Center & Research Institute, is doing just that in an investigation concerning the human papillomavirus (HPV).

7 Mar 2005

Batches of the drugs Paxil and Avandamet seized by federal officials

Batches of the drugs Paxil CR and Avandamet United States, were seized by marshals at manufacturing and distribution plants in Tennessee and Puerto Rico after federal officials said the manufacturer failed to correct violations of production safety standards.

5 Mar 2005

Antidepressants prescribed to children will have Black Box labels warnings

Antidepressants prescribed to children should have "Black box" labels warnings, which are reserved for the most dangerous drugs, of the increased risk of suicide that they pose. This will happen mid-March, five months after the Food and Drug Administration ordered it.

3 Mar 2005

Kidney dysfunction in HIV patients can be detected earlier

Tracking the subtle kidney damage that can lead to chronic kidney disease in HIV patients is increasingly important as people survive longer and may have an increased risk of renal dysfunction as a result of their disease, therapy-related damage, or co-morbid conditions such as diabetes mellitus and hypertension.

28 Feb 2005

Stop-smoking products increase quit rate for smokers who need to quit the most

An article in the current issue of the Journal of Substance Abuse Treatment (Volume 28, Issue 1, 2005) provides new hope for smokers who are highly dependent upon tobacco and who smoke more than two packs per day.

21 Feb 2005

Tentative approval of co-packaged lamivudine/zidovudine fixed dose combination tablets and nevirapine tablets

The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.

26 Jan 2005

Researchers attack cervical cancer

As more and more promising results of clinical trials on vaccination against human papillomaviruses are published, the more likely it becomes that an HPV vaccine will be the first licensed immunization against a sexually transmitted disease.

17 Jan 2005

States to explore putting restrictions on AIDS drug Trizivir

AIDS Healthcare Foundation (AHF) has sent a letter dated October 20, 2004, to the heads of all state Medicaid programs asking them put in use treatment authorization request (TAR) procedures on GlaxoSmithKline's (GSK) fixed-dose combination AIDS drug, Trizivir, as a standalone regimen for treatment naïve patients.

6 Jan 2005

Information submitted via new drug applications could easily be made accessible to the public

A researcher at Oregon Health & Science University and the Portland Veterans Affairs Medical Center is calling upon the U.S. Food and Drug Administration (FDA) to share more information provided by pharmaceutical companies regarding their clinical drug trials.

28 Dec 2004

GlaxoSmithKline acquires full marketing and development rights for BEXXAR worldwide

GlaxoSmithKline announced that it has reached an agreement with Corixa Corporation to acquire worldwide rights and responsibilities related to the manufacturing, development and commercialization of the BEXXAR® therapeutic regimen.

14 Dec 2004

HHS purchases 1.2 million doses of GSK's Fluarix flu vaccine

HHS Secretary Tommy G. Thompson has announced that the Food and Drug Administration authorized the use of GlaxoSmithKline influenza vaccine, Fluarix, in the United States under an Investigational New Drug application.

8 Dec 2004

FDA commits to use of radio frequency identification (RFID) technology

The U.S. Food and Drug Administration (FDA) is stepping up its efforts to improve the safety and security of the nation's drug supply through the use of radio frequency identification (RFID) technology.

16 Nov 2004

Number of overdoses among opiate and injecting drug users has risen nearly 100 fold in thirty years

Researchers from Imperial College London, the Health Protection Agency, Medical Research Council and GlaxoSmithKline have analysed the numbers of opiate and injecting drug users who had overdoses, to see if it was possible to model long term trends for the number of opiate or injecting drug users.

14 Nov 2004

Study shows possible solution to the current flu vaccine shortage

A new study led by the Saint Louis University’s Center for Vaccine Development may provide a solution to the current flu vaccine shortage in the U.S. The team found a possible way to double the available supply of influenza vaccine for adults between the ages of 18 and 60.

4 Nov 2004

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.

26 Oct 2004

Discovery might improve design, effectiveness of anti-cancer drugs

Working with an enzyme that degrades anti-cancer drugs in humans, University of North Carolina at Chapel Hill biochemists and colleagues have made a discovery that they believe eventually could help improve such drugs’ design and effectiveness.

18 Oct 2004

Glaxo drops appeal in AIDS drug pricing case

A landmark South African legal complaint against British drug maker GlaxoSmithKline (GSK) over its AIDS drug pricing and policies in that country will proceed after GSK dropped its public and repeated vows to appeal a decision allowing the case to go forward.

22 Sep 2004

GlaxoSmithKline has granted a voluntary licence to Cosmos Limited for the manufacture and sale of antiretrovirals

GlaxoSmithKline currently sells zidovudine (sold as Retrovir®), lamivudine (sold as Epivir®) and the combination of the two molecules (sold as Combivir®) across the region.

22 Sep 2004

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Roche and GlaxoSmithKline announced today the submission of a Marketing Authorisation Application to the European authorities for a novel, once-monthly oral formulation of their new bisphosphonate, Bonviva (ibandronate), for the treatment of postmenopausal osteoporosis.

20 Sep 2004